Biotechnology

Elevian Announces $15 Million Equity Financing

GDF11, Biotechnology, Biology, Life sciences
Tuesday, November 24, 2020 - 2:00pm

ALLSTON, Mass., Nov. 24, 2020 /PRNewswire/ -- Elevian , an emerging biotech company developing medicines that restore youthful regenerative capacity with the potential to treat and prevent multiple age-related diseases, today announced the closing of a $15 million equity financing.

Key Points: 
  • ALLSTON, Mass., Nov. 24, 2020 /PRNewswire/ -- Elevian , an emerging biotech company developing medicines that restore youthful regenerative capacity with the potential to treat and prevent multiple age-related diseases, today announced the closing of a $15 million equity financing.
  • Proceeds from the equity financing will enable Elevian to advance recombinant GDF11 (rGDF11) toward the clinic to treat stroke and other age-related diseases.
  • In conjunction with the financing, Elevian has appointed Suzanne Fletcher and Dan Marshak to its board of directors.
  • Elevian is an emerging biotech company developing medicines that restore youthful regenerative capacity, with the potential to treat and prevent multiple age-related diseases.

OncoSec Announces Exclusive License Agreement for Cliniporator® Gene Electrotransfer Platform Developed by IGEA Clinical Biophysics

Biology, Biotechnology, Life sciences, Electroporation, Gene delivery, Microbiology, Molecular biology, Natural sciences
Tuesday, November 24, 2020 - 2:00pm

PENNINGTON, N.J. and SAN DIEGO, Nov. 24, 2020 /PRNewswire/ --OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company developing intra-tumoral cancer immunotherapies, today announced that it has licensed the exclusive rights to the Cliniporator electroporation or gene electrotransfer platform from IGEA Clinical Biophysics ("IGEA").

Key Points: 
  • PENNINGTON, N.J. and SAN DIEGO, Nov. 24, 2020 /PRNewswire/ --OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company developing intra-tumoral cancer immunotherapies, today announced that it has licensed the exclusive rights to the Cliniporator electroporation or gene electrotransfer platform from IGEA Clinical Biophysics ("IGEA").
  • The license encompasses a broad field of use for gene delivery in oncology, including use as part of OncoSec's visceral lesion applicator (VLA) program.
  • IGEA has clinical experience with gene therapy as well, which OncoSec will build on.
  • Ruggero Cadossi, M.D., IGEA President, added, "We are proud to collaborate with OncoSec, a company committed to delivering innovative therapies to cancer patients.

Todos Medical Completes Installation of Lab Automation Equipment at Wisconsin Lab Client to Support COVID-19 PCR Testing

Articles, Branches of biology, Natural sciences, Biotechnology, Laboratory techniques, Molecular biology, Amplifiers, Hoffmann-La Roche, Polymerase chain reaction, COVID-19 testing, Coronavirus disease, Revolutionary Communist Party of Argentina
Tuesday, November 24, 2020 - 2:00pm

Concurrent with this announcement, the Company announced that it has secured a proprietary supply chain for the most in-demand lab consumable products required to conduct PCR testing.

Key Points: 
  • Concurrent with this announcement, the Company announced that it has secured a proprietary supply chain for the most in-demand lab consumable products required to conduct PCR testing.
  • An international shortage of lab consumables has emerged as the key rate limiting steps for laboratories to increase their PCR testing capacity worldwide.
  • We are very excited with the progress we are making in our base PCR lab testing business.
  • For information related to Todos Medicals COVID-19 testing capabilities, please visit www.todoscovid19.com
    For testing and PPE inquiries, please email sales@todosmedical.com.

Key Regulatory Body in India Grants Commercial License for Fluidigm Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay

Natural sciences, Laboratory techniques, Physical sciences, Chemistry, Molecular biology, Biotechnology, Coronavirus disease, Reverse transcription polymerase chain reaction, Assay, Central Drugs Standard Control Organisation, Polymerase chain reaction
Tuesday, November 24, 2020 - 1:30pm

In India, the CDSCO leads regulatory approval for vaccines, diagnostics, prophylactics, and therapeutics designed to prevent or treat diseases including COVID-19.

Key Points: 
  • In India, the CDSCO leads regulatory approval for vaccines, diagnostics, prophylactics, and therapeutics designed to prevent or treat diseases including COVID-19.
  • The Fluidigm test is one of the first saliva-based tests for COVID-19 to be licensed in India.
  • Fluidigms much-needed noninvasive saliva-based test comes at a critical time in the pandemic, and we are pleased to be able to facilitate availability of the Advanta assay in India.
  • License to market our Advanta Dx SARS-CoV-2 RT-PCR Assay in the worlds second-most populous nation will enable an effective and scalable way to get noninvasive saliva-based testing across India as a possible second wave of infections approaches.

bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting

Biotechnology, Health, Genetics, Pharmaceutical, Clinical trials, Stephen Stills, Bluebird bio, Bluebird, Songs, Rock music
Tuesday, November 24, 2020 - 1:00pm

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast on December 7, 2020 at 7:00 p.m.

Key Points: 
  • bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast on December 7, 2020 at 7:00 p.m.
  • ET to review clinical data presented at the 62nd American Society of Hematology Annual Meeting and Exposition.
  • To access the live webcast of bluebird bios presentation, please visit the Events & Presentations page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com .
  • bluebird bio is a trademark of bluebird bio, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005587/en/

Otsuka Pharmaceutical Development & Commercialization, Inc., and the Columbia University Mailman School of Public Health Enter Into a Global Pharmacovigilance Agreement

Oncology, Education, Health, Pharmaceutical, University, Biotechnology, Columbia University, NewYork–Presbyterian Healthcare System, Washington Heights, Manhattan, Health, Manhattan, Pharmaceuticals policy, Clinical research, Otsuka Pharmaceutical, Pharmacovigilance, Columbia University Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, Taiho Pharmaceutical
Tuesday, November 24, 2020 - 1:00pm

The three-year agreement, through October 2022, draws on the extensive expertise of faculty at Columbia Mailman and the Columbia University Irving Medical Centers Vagelos College of Physicians and Surgeons.

Key Points: 
  • The three-year agreement, through October 2022, draws on the extensive expertise of faculty at Columbia Mailman and the Columbia University Irving Medical Centers Vagelos College of Physicians and Surgeons.
  • The expertise and scientific depth of the Columbia University Irving Medical Center faculty will help us enhance the epidemiological support for various Otsuka Global Pharmacovigilance regulatory reports and publications, said Mirza I. Rahman, MD, MPH, senior vice president and chief global pharmacovigilance officer, Otsuka Pharmaceutical Development & Commercialization, Inc., and a Columbia University Mailman School of Public Health alumnus.
  • Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: Otsukapeople creating new products for better health worldwide.
  • Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI).

Twist Bioscience to Present at Upcoming Virtual Investor Conferences

Technology, Research, Genetics, Nanotechnology, Biotechnology, Health, Pharmaceutical, Other Science, Science, Articles, Twist Bioscience, Branches of biology, Life sciences, Synthetic biology, Evercore, Genomics
Tuesday, November 24, 2020 - 1:00pm

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming virtual investor conferences:

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming virtual investor conferences:
    Piper Sandler 32nd Annual Virtual Healthcare Conference, recorded fireside chat available at 8:00 a.m.
  • ET on Monday, November 30
    2020 Evercore ISI HealthCONx Conference on Tuesday, December 1 at 1:50 p.m.
  • ET
    Both presentations can be accessed by visiting the Investor Calendar page of the investor relations section of the companys website here .
  • Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.

Gamida Cell to Present at Upcoming Conferences

Biotechnology, Pharmaceutical, Health, Oncology, Life sciences, Branches of biology, Health sciences, Biotechnology, Cell biology, Blood, Stem cells, Medicinal chemistry, Therapy, Hematology, Cell therapy, Cancer
Tuesday, November 24, 2020 - 1:01pm

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Chief Executive Officer of Gamida Cell, will present at two virtual conferences in December:

Key Points: 
  • Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Chief Executive Officer of Gamida Cell, will present at two virtual conferences in December:
    Evercore ISI 3rd Annual HealthCONx Conference, fireside chat at 12:10 p.m.
  • A webcast of each presentation will be available in the Investors & Media section of the Gamida Cell website, www.gamida-cell.com , and will be available for at least 14 days following the event.
  • Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases.
  • For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn or Twitter at @GamidaCellTx .

Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1

Oncology, Health, Diabetes, Genetics, Research, Science, Biotechnology, Branches of biology, Biology, Life sciences, Bioethics, Biotechnology, Gene therapy, Molecular biology, Two River, BioMarin Pharmaceutical
Tuesday, November 24, 2020 - 1:16pm

Genprex, Inc. (Genprex or the Company) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company will participate at the Diamond Equity Research Emerging Growth Invitational taking place virtually on December 1, 2020.

Key Points: 
  • Genprex, Inc. (Genprex or the Company) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company will participate at the Diamond Equity Research Emerging Growth Invitational taking place virtually on December 1, 2020.
  • A live audio webcast and archive of the conference presentation will be available for a period of time using the registration link above.
  • For more information on the Diamond Equity Research Emerging Growth Invitational, please contact your Diamond Equity Research representative.
  • Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

Oculis to Present Progress in its Portfolio of Novel Topical Treatments for Retinal and Front-of-the-Eye Diseases at Upcoming Investor Conferences

Medical specialties, Clinical medicine, Medicine, Autoimmune diseases, Syndromes, Biotechnology, Immune system, Immunology, TNF inhibitor, Sjögren syndrome
Tuesday, November 24, 2020 - 1:00pm

www.pipersandler.com

Key Points: 
  • www.pipersandler.com
    Dr. Sherif will provide an overview of Oculis portfolio and the significant progress it has made during 2020 with the advancement of its lead candidates OCS-01 and OCS-02.
  • Dr. Sherif will also discuss progress with OCS-02, a novel and a potentially first-in-class topical anti-TNF alpha antibody.
  • Oculis novel topical (eye drop) treatments are non-invasive and represent an unprecedented technical advance for patients with retinal and front-of-the-eye diseases.
  • Oculis has an experienced management team from global ophthalmic companies and is supported by leading international life science investors.